Senseonics Holdings (SENS) Panoramica del titolo
Senseonics Holdings, Inc. è un'azienda di tecnologia medica in fase di sviluppo commerciale e si concentra sullo sviluppo e sulla produzione di sistemi di monitoraggio continuo del glucosio (CGM) per persone affette da diabete negli Stati Uniti e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
SENS Community Fair Values
Create NarrativeSee what 31 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Senseonics Holdings, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$5.03 |
| Massimo di 52 settimane | US$11.58 |
| Minimo di 52 settimane | US$4.79 |
| Beta | 0.99 |
| Variazione di 1 mese | -6.16% |
| Variazione a 3 mesi | -1.37% |
| Variazione di 1 anno | -48.55% |
| Variazione a 3 anni | -70.42% |
| Variazione a 5 anni | -92.19% |
| Variazione dall'IPO | -92.26% |
Notizie e aggiornamenti recenti
Seeking Alpha • Jul 14
Senseonics: Implantable Sensor, Unsustainable Spend
Summary Senseonics Holdings is a Sell, with persistent concerns about cash burn, dilution, and lack of profitability. SENS's direct-to-consumer strategy and in-house commercialization have driven high SG&A, with 2026 cash burn projected up to $120 million on $60–64 million revenue. Gross margins improved to 58% in Q1, but sustained growth remains highly dependent on heavy investment and infrastructure buildout. Pipeline products Gemini (2027) and Freedom (2028) could boost adoption, but no near-term inflection in revenue/opex is evident. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 14
SENS: Future Margins And Revenue Mix Will Drive Upside Potential
The analyst price target for Senseonics Holdings has been revised lower by several dollars per share. Analysts cite updated assumptions on fair value, revenue growth, profit margins, and a reduced future P/E multiple as the key drivers of this change.
Aggiornamento narrativa • Jun 30
SENS: Long-Duration CGM Data Will Support Future Margin Upside
Senseonics Holdings' updated analyst price target has moved lower by about $5.10 to $13.80, as analysts factor in revised expectations for fair value, revenue growth, profit margins, and future P/E assumptions following recent target cuts from several firms. Analyst Commentary Recent research updates on Senseonics Holdings focus on how its current trading level compares with revised views on fair value, revenue potential, profitability, and assumed P/E multiples.
Aggiornamento narrativa • Jun 16
SENS: Long Wear CGM Execution Will Support Future Profitability Repricing Potential
Analysts have trimmed their average price target on Senseonics Holdings stock by a few dollars, citing updated expectations that reflect modest adjustments to revenue growth, profit margin, discount rate, and future P/E assumptions. Analyst Commentary Recent research updates on Senseonics Holdings highlight that even with lower price targets, some bullish analysts still see potential drivers that they believe could support the stock if the company executes on its plans.Recent updates
Seeking Alpha • Jul 14
Senseonics: Implantable Sensor, Unsustainable Spend
Summary Senseonics Holdings is a Sell, with persistent concerns about cash burn, dilution, and lack of profitability. SENS's direct-to-consumer strategy and in-house commercialization have driven high SG&A, with 2026 cash burn projected up to $120 million on $60–64 million revenue. Gross margins improved to 58% in Q1, but sustained growth remains highly dependent on heavy investment and infrastructure buildout. Pipeline products Gemini (2027) and Freedom (2028) could boost adoption, but no near-term inflection in revenue/opex is evident. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 14
SENS: Future Margins And Revenue Mix Will Drive Upside Potential
The analyst price target for Senseonics Holdings has been revised lower by several dollars per share. Analysts cite updated assumptions on fair value, revenue growth, profit margins, and a reduced future P/E multiple as the key drivers of this change.Aggiornamento narrativa • Jun 30
SENS: Long-Duration CGM Data Will Support Future Margin Upside
Senseonics Holdings' updated analyst price target has moved lower by about $5.10 to $13.80, as analysts factor in revised expectations for fair value, revenue growth, profit margins, and future P/E assumptions following recent target cuts from several firms. Analyst Commentary Recent research updates on Senseonics Holdings focus on how its current trading level compares with revised views on fair value, revenue potential, profitability, and assumed P/E multiples.Aggiornamento narrativa • Jun 16
SENS: Long Wear CGM Execution Will Support Future Profitability Repricing Potential
Analysts have trimmed their average price target on Senseonics Holdings stock by a few dollars, citing updated expectations that reflect modest adjustments to revenue growth, profit margin, discount rate, and future P/E assumptions. Analyst Commentary Recent research updates on Senseonics Holdings highlight that even with lower price targets, some bullish analysts still see potential drivers that they believe could support the stock if the company executes on its plans.Aggiornamento narrativa • Jun 02
SENS: Long Wear CGM Execution Will Drive Future Profitability And Repricing
The analyst price target for Senseonics Holdings has been reduced by $11, with analysts citing updated fair value estimates, a lower future P/E assumption, and recent Street research that reset targets at H.C. Wainwright, Stifel, and Lake Street. Analyst Commentary Recent Street research on Senseonics Holdings points to a reset in price targets that reflects updated fair value work, revised P/E assumptions, and refreshed views on execution risk and potential growth.Aggiornamento narrativa • May 17
SENS: Long Wear CGM Adoption Will Drive Future Profitability And Repricing
Senseonics Holdings' consensus analyst price target has been reduced by several dollars, with analysts citing updated assumptions for revenue growth, profitability, and valuation multiples as key reasons for the lower fair value outlook. Analyst Commentary Even with the recent cuts to price targets, bullish analysts still see potential for Senseonics Holdings to create value if the company executes on its growth and profitability plans.Aggiornamento narrativa • Apr 29
SENS: Long Wear CGM Adoption And AID Integration Will Drive Upside
Analysts have slightly adjusted their price target for Senseonics Holdings to $31.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E multiples, while keeping the overall fair value view steady. What's in the News First European launch of the Eversense 365 CGM system, described as the world’s first and only one year CGM, starting with patients in Sweden and with rollouts planned in Germany, Spain and Italy in the coming weeks (Key Developments).Aggiornamento narrativa • Apr 13
SENS: Real World CGM Use And AID Access Will Drive Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing updated assumptions that now reflect slightly different discount rate, revenue growth, profit margin, and future P/E inputs in their models. What's in the News The board is asking stockholders to approve a change to the Certificate of Incorporation to increase authorized common shares to 140,000,000 from 70,000,000, with the meeting set for May 20, 2026 (Key Developments).Aggiornamento narrativa • Mar 30
SENS: Long-Duration CGM Data Will Support Future Automated Delivery Upside
Analysts have modestly adjusted their price target on Senseonics Holdings to $18.92, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value view steady. What's in the News New real world evidence data for the Eversense 365 CGM system reports an average transmitter wear time of 93.8% over one year, a mean Glucose Management Indicator of 7.14% and a mean Time in Range of 66% across 5,059 sensors used in the US, with over 75% of users reaching hypoglycemic targets (Key Developments).Aggiornamento narrativa • Mar 16
SENS: Real World CGM Outcomes And AID Adoption Will Support Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing slightly higher assumed discount rates, a modest adjustment in expected revenue growth and profit margins, and a small shift in future P/E assumptions as the main factors behind their updated view. What's in the News New real world evidence data on more than 5,000 Eversense 365 sensors in US patients showed high adherence, a mean Glucose Management Indicator of 7.14% and Time in Range of 66%, with over 75% of users meeting hypoglycemia targets across a full year of use (Key Developments).Aggiornamento narrativa • Mar 02
SENS: Long-Duration CGM Access Will Drive Future Automated Delivery Upside
Analysts have modestly adjusted their price target on Senseonics Holdings to $18.92 per share. This reflects slightly different assumptions on discount rate, revenue growth, profit margin and future P/E, while keeping their overall valuation view broadly unchanged.Aggiornamento narrativa • Feb 16
SENS: Internalized Commercial Model And AID Launch Will Drive Long-Term Upside
Analysts have maintained their $31.00 price target on Senseonics Holdings, citing largely unchanged fair value assumptions, along with small adjustments to the discount rate, revenue growth, profit margin, and future P/E inputs. What's in the News Senseonics issued 2026 guidance, with expected full year global net revenue of about US$58 million to US$62 million, linked to the planned transition of Eversense commercialization from Ascensia starting January 1, 2026 (Corporate guidance).Aggiornamento narrativa • Feb 02
SENS: Long-Duration CGM Execution Risk Will Set Up Future Upside Potential
Analysts have trimmed their 12 month target on Senseonics to US$15 from US$25, citing updated sales multiples on 2028 estimates and a higher 12% discount rate to reflect commercial execution risk following the recent stock split. Analyst Commentary Bullish Takeaways Bullish analysts still see upside potential at US$15, even after trimming the target from US$25.Aggiornamento narrativa • Jan 18
SENS: Long-Duration CGM Share Gains Will Support Future Upside Potential
Analysts have trimmed their average price target on Senseonics to about $18.92. This reflects updated models that factor in lower sales multiples, a roughly 12% discount rate to account for commercial execution risk, and expectations around future product adoption and capital needs.Articolo di analisi • Jan 13
Senseonics Holdings, Inc.'s (NASDAQ:SENS) Share Price Could Signal Some Risk
You may think that with a price-to-sales (or "P/S") ratio of 9.9x Senseonics Holdings, Inc. ( NASDAQ:SENS ) is a stock...Aggiornamento narrativa • Jan 04
SENS: Internalized Commercial Model Will Drive Long Term Upside Potential
Analysts have trimmed their price target on Senseonics Holdings to $15.00 from $25.00, citing updated long term growth assumptions, a higher perceived discount rate to reflect commercial execution risk, and the need for additional capital as the company internalizes commercial operations despite favorable physician feedback on Eversense and Gemini. Analyst Commentary Bullish analysts acknowledge the reduced price targets but emphasize that the stock still offers meaningful upside from current levels, with valuation supported by long term revenue growth expectations for Eversense and the upcoming Gemini platform.Aggiornamento narrativa • Dec 21
SENS: Long-Duration CGM Share Gains Will Drive Future Upside Potential
Analysts have modestly reduced their price target on Senseonics Holdings to $15 from $25, reflecting updated sales multiple assumptions, a higher discount rate to account for commercial execution risk, and a more cautious view on funding needs as the company prepares to take commercial operations back in house. Analyst Commentary Street research reflects a mixed but engaged view on Senseonics, with valuation resets largely tied to updated sales assumptions, perceived execution risk, and the capital intensity of bringing commercialization back in house.Articolo di analisi • Dec 09
Is Senseonics Holdings (NASDAQ:SENS) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aggiornamento narrativa • Dec 07
SENS: Long-Duration CGM Share Gains Will Drive Future Upside Potential
Analysts have modestly reduced their average price target for Senseonics Holdings to about $18.92 per share from roughly $25.00. They cite recalibrated sales multiples, a slightly higher risk premium around commercial execution, and the need for additional capital as the company internalizes commercialization and invests in next-generation sensor platforms.Aggiornamento narrativa • Nov 23
SENS: Market Share Gains Will Drive Long-Term Revenue Expansion
Analysts have revised their price target for Senseonics Holdings lower. They note that updated sales estimates and higher perceived commercial risk have led to a reduction from approximately $25 to below $19 per share.Aggiornamento narrativa • Nov 03
SENS: Future Commercial Rollout Will Drive Diabetes Monitoring Adoption
Analysts have revised their price target for Senseonics Holdings downward from $28.60 to $25.33 per share, citing expected financial impacts from the company's assumption of commercial operations. This is balanced by continued optimism over the Eversense 365 system's market potential.Aggiornamento narrativa • Oct 20
Continuous Glucose Monitoring Will Redefine Preventive Diabetes Care
Analysts have significantly increased their price target for Senseonics Holdings from $1.43 to $28.60. They cite growing confidence in the company's expanding product offerings and anticipated demand for its Eversense 365 sensor system.Aggiornamento narrativa • Aug 08
Continuous Glucose Monitoring Will Redefine Preventive Diabetes Care
The downward revision in Senseonics Holdings’ price target reflects a combination of lowered future earnings multiples and a higher discount rate, resulting in the consensus fair value estimate declining from $1.55 to $1.41. What's in the News Senseonics Holdings completed a $50 million follow-on equity offering, issuing 100 million common shares at $0.50 per share with a $0.03 discount.
Nuova narrativa • Mar 28
Eversense 365 Will Expand Patient Access With EU Launch
U.S. launch and future EU expansion of Eversense 365 could drive revenue growth through increased adoption and international market presence.Rendimenti per gli azionisti
| SENS | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 3.5% | 3.9% | 1.0% |
| 1Y | -48.5% | -14.5% | 19.1% |
Ritorno vs Industria: SENS ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -14.5 % nell'ultimo anno.
Rendimento vs Mercato: SENS ha avuto una performance inferiore al mercato US che ha registrato un rendimento 19.1 % nell'ultimo anno.
Volatilità dei prezzi
| SENS volatility | |
|---|---|
| SENS Average Weekly Movement | 11.1% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di SENS è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 11% ) di SENS è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1996 | 130 | Tim Goodnow | www.senseonics.com |
Senseonics Holdings, Inc. è un'azienda di tecnologia medica in fase di sviluppo commerciale e si concentra sullo sviluppo e sulla produzione di sistemi di monitoraggio continuo del glucosio (CGM) per persone affette da diabete negli Stati Uniti e a livello internazionale. I suoi prodotti comprendono Eversense, Eversense XL, Eversense E3 e Eversense 365, sistemi CGM impiantabili che misurano i livelli di glucosio nelle persone con diabete attraverso un sensore sottopelle, un trasmettitore intelligente rimovibile e ricaricabile e un'applicazione per il monitoraggio e la gestione del diabete in tempo reale. L'azienda serve gli operatori sanitari e i pazienti attraverso una rete di distributori e partner strategici.
Senseonics Holdings, Inc. Riepilogo dei fondamenti
| SENS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$264.67m |
| Utili (TTM) | -US$87.19m |
| Ricavi(TTM) | US$40.71m |
6.4x
Rapporto P/S-3.0x
Rapporto P/ESENS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SENS Conto economico (TTM) | |
|---|---|
| Ricavi | US$40.71m |
| Costo del fatturato | US$19.51m |
| Profitto lordo | US$21.20m |
| Altre spese | US$108.39m |
| Utili | -US$87.19m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
Aug 06, 2026
| Utile per azione (EPS) | -1.67 |
| Margine lordo | 52.07% |
| Margine di profitto netto | -214.16% |
| Rapporto debito/patrimonio netto | 104.6% |
Come si è comportato SENS nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/31 10:32 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Senseonics Holdings, Inc. è coperta da 16 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Matthew Miksic | Barclays |
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |